Boomerang Medical raises $20M Series B for neuromodulation in inflammatory bowel disease
Summary
Boomerang Medical raised $20 million in Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. The Mountain View, California-based women-led bioelectronic medicine company is developing an implantable sacral neuromodulation system to treat ulcerative colitis and Crohn's disease. Proceeds will advance the BOOM-IBD2 pivotal trial, the first pivotal trial of implantable neuromodulation in inflammatory bowel disease.
Why it matters
Boomerang Medical is pursuing the first device-based treatment for IBD, a chronic autoimmune disease affecting millions that currently has no neuromodulation options. Building on a completed 40-patient feasibility study and leveraging the established safety profile of over 500,000 sacral neuromodulation procedures, the company was named 'Emerging Leader in IBD' by the Crohn's & Colitis Foundation - the first medical device company to receive this recognition.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial